Answers are grounded in this paper and cite their sources.
Retrospective study found high agreement in FVIII activity measurement between one-stage clot-based and chromogenic assays, suggesting reliability in clinical settings.
A number of gene therapy studies have shown discrepancies between the one-stage and chromogenic factor VIII (FVIII) assays. Studies comparing the two assays are of small sample size. We aimed to compare the one-stage clot-based assay with the chromogenic assay in measuring FVIII activity in blood sample in a single tertiary academic centre. This is a single-centre retrospective study conducted at Sultan Qaboos University Hospital. Both assays performed FVIII measurements at the SQUH from March 2009 to March 2018. A total of 3623 samples from a range of haematologic conditions had both assays performed. The median age of all patients was 26 years (IQR: 17-37). The mean FVIII activity by one-stage clot-based and chromogenic assays were 1.2 IU/ml (SD: 0.6) and 1.2 IU/ml (SD: 0.5), respectively. Bland-Altman analysis showed excellent agreement with a very minimal bias of -0.0034. High baseline FVIII activity and the diagnosis predicted disagreement between the two assays (P values < 0.001). Positive ANA and FVIII inhibitor had no impact on the disagreement (P value = 0.2 and 0.7, respectively). A subgroup analysis of samples with FVIII activity of <0.4 IU/ml showed 21.1% discrepancy with the majority (75.8%) of samples showing overestimated results by the OSA. One-stage clot-based and chromogenic FVIII assays showed excellent agreement for measuring FVIII activity.
No takes yet. Share an insight, caveat, or question.
Buraidi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: